Glycos Biotechnologies Raises $2.35M

Houston-based Glycos Biotechnologies, a developer of bacterial strains used for producing chemicals and biofuels, has raised $2.35M as part of a venture round worth $3.25M. The funding was disclosed in a regulatory filing today. Details on the funding have not yet been released by the company. The firm says on its web site that it is funded by DFJ Mercury and DFJ. Dan Watkins of DFJ Mercury and Steve Jurvetson of Draper Fisher Jurvetson are listed as board members of the firm. More information »